RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is Dece ...

Core Viewpoint - The article discusses a class action lawsuit against Edwards Lifesciences Corporation, alleging violations of the Securities Exchange Act of 1934 by the company and its executives during a specified class period. Group 1: Lawsuit Details - The class action lawsuit is titled Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), and it involves purchasers of Edwards Lifesciences securities from February 6, 2024, to July 24, 2024 [1] - Investors have until December 13, 2024, to seek appointment as lead plaintiff in the lawsuit [1] - The lawsuit alleges that Edwards Lifesciences made false or misleading statements regarding its revenue outlook and growth potential, particularly concerning its Transcatheter Aortic Valve Replacement (TAVR) product [4][3] Group 2: Allegations Against the Company - The lawsuit claims that the defendants created a false impression of reliable information regarding projected revenue and growth while downplaying risks from seasonality and macroeconomic factors [4] - It is alleged that TAVR's growth was at risk of deceleration, and the company's optimistic reports did not align with actual performance, particularly in the second quarter of 2024 [4] - On July 24, 2024, Edwards Lifesciences disclosed TAVR results that fell below expectations and lowered its fiscal year 2024 projections, leading to a stock price drop of over 31% [5] Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Edwards Lifesciences securities during the class period to seek lead plaintiff status [6] - Robbins Geller Rudman & Dowd LLP is the law firm representing investors in this case, known for securing significant monetary relief for investors in securities fraud cases [7]

Core Viewpoint - Edwards Lifesciences Corporation is facing a class action securities lawsuit due to alleged securities fraud that impacted investors between February 6, 2024, and July 24, 2024 [1] Group 1: Lawsuit Details - The lawsuit claims that the defendants misled investors regarding Edwards' expected revenue for fiscal year 2024, particularly concerning the growth of the Transcatheter Aortic Valve Replacement (TAVR) platform [2] - On July 24, 2024, Edwards reported disappointing financial results for Q2 2024 and significantly reduced its revenue guidance for the TAVR platform for the full fiscal year 2024 [2] - The company attributed the TAVR setback to the growth of structural heart therapies, which strained hospital workflows and led to underutilization of TAVR despite claims of an undertreated patient population [2] Group 2: Market Reaction - Following the announcement of the financial results and revenue guidance cut, Edwards' stock price plummeted from $86.95 per share on July 24, 2024, to $59.70 per share on July 25, 2024, marking a decline of approximately 31.34% in one day [2] Group 3: Next Steps for Investors - Investors who suffered losses during the relevant period have until December 13, 2024, to request appointment as lead plaintiff in the lawsuit [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 4: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States [4]

Lawsuit Overview - A securities class action lawsuit has been filed against Edwards Lifesciences Corporation (NYSE: EW) on behalf of investors who purchased or acquired Edwards securities between February 6, 2024, and July 24, 2024 [1] - The lead plaintiff deadline is December 13, 2024 [1] Alleged Misconduct - Defendants are accused of providing overly positive statements about the growth of Edwards' core product, Transcatheter Aortic Valve Replacement (TAVR), while allegedly concealing material adverse facts about the true state of the TAVR platform [3] - Edwards' claims were allegedly based on an overestimation of the low-treatment-rate patient population and the willingness of hospitals to continue using TAVR over newer treatment alternatives [3] Lead Plaintiff Process - Edwards investors may seek to be appointed as a lead plaintiff representative by December 13, 2024 [4] - The lead plaintiff acts on behalf of all class members and selects counsel to represent the class [4] Law Firm Information - Kessler Topaz Meltzer & Check, LLP is prosecuting the class action and encourages investors with significant losses to contact the firm for more information [5][6] - The firm has a global reputation for recovering billions of dollars for victims of fraud and corporate misconduct [6]

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

NEW YORK, Nov. 4, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW).Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=110313&from=4 CLASS PERIOD: Febru ...

Lawsuit Overview - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws [1] - The lawsuit is pending in the U S District Court for the Central District of California under the case Patel v Edwards Lifesciences Corporation et al No 24-cv-02221 [2] - Investors have until December 13 2024 to ask the Court to be appointed as lead plaintiff [2] Allegations Against Edwards Lifesciences - Edwards Lifesciences is accused of making materially false and misleading statements regarding its TAVR platform and its ability to capitalize on unmet demand [4] - The company allegedly overstated the demand and growth potential of TAVR while its patient activation activities failed to reach the low-treatment-rate population [4] - Healthcare organizations prioritized other treatments over TAVR leading to underutilization despite the company's claims of a significantly undertreated patient population [5] Financial Impact - On July 24 2024 Edwards Lifesciences slashed its guidance for TAVR for fiscal 2024 and announced disappointing financial results for TAVR in fiscal 2Q 24 [5] - The news caused a 31% decline in Edwards stock price from $86 95 per share on July 24 2024 to $59 70 per share on July 25 2024 [6] Company Background - Edwards Lifesciences is an international company that researches develops and provides products and technologies for heart valve repair and replacement therapies as well as critical care monitoring solutions [3] - The company categorizes its therapies and technologies into four segments: Transcatheter Aortic Valve Replacement (TAVR) Transcatheter Mitral and Tricuspid Therapies (TMTT) Surgical Structural Heart therapies and Critical Care therapies [3] Legal Representation - Bleichmar Fonti & Auld LLP is representing plaintiffs in this securities class action and shareholder litigation [8] - The firm has a track record of recovering significant amounts in similar cases including $900 million from Tesla Inc's Board of Directors and $420 million from Teva Pharmaceutical Ind Ltd [8]

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/edwards-lifescie ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=109666&from=3 CLASS PERIO ...